MMR-2007 08A, August 2007
Line Item Billing Requirement for Epoetin Alfa (EPO) Submitted on End Stage Renal Disease (ESRD) Claims (MM5545) Provider Types Affected Provider Action Needed Background You can find an MLN Matters article related to CR5039
at http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5039.pdf Line item billing allows for EPO to be billed the same way as all other separately payable drugs. For claims with dates of service on or after January 1, 2008, RDFs will bill for each administration of EPO on a separate line of the 72X type of bill indicating the line item date of service for the administration. The units reported on the claim line for EPO are multiplied by the total units defined by the Healthcare Common Procedure Coding System (HCPCS) to reflect the dosage per administration. Medicare will then calculate the EPO payment based on the units reported on the line for 72X claims with dates of service on or after January 1, 2008. RDFs are no longer required to report value code 68 with the total monthly dosage with dates of service on or after January 1, 2008. The total number of administrations of EPO will be determined by the total number of lines on the claim billing for EPO. When RDFs report the GS modifier, it is not required to be
reported on every EPO line item. The GS modifier should be reported
on the line item(s) that represent an administration of EPO at
the reduced dosage following existing instructions in the Medicare
Claims Processing Manual (Chapter 8, Section 60.4; http://www.cms.hhs.gov/manuals/downloads/clm104c08.pdf Supplies of EPO and Aranesp for self-administration should be billed according to the pre-determined schedule in the plan-of-care provided to the beneficiary. RDFs should submit a separate line item for each date an administration is expected to be performed with the expected dosage. In the event that the schedule was changed, the provider should note the changes in the medical record and bill according to the revised schedule. For patients beginning to self administer EPO or Aranesp at home who are receiving an extra month supply of the drug, RDFs should:
Note that Medicare will return claims to the provider containing more than one EPO or Aranesp line with the EM modifier for claims with dates of service on or after January 1, 2008. RDFs should include condition code 70 on claims billing for home dialysis patients that self-administer anemia management drugs, including EPO and Aranesp. Note that the electronic form required for billing ESRD claims is the ANSI X12 837 Institutional claim transaction. The data structure of that transaction is difficult to express in narrative form. In addition, small providers who are excepted from the requirement to submit electronic claims, CMS provides instructions in CR5545 relative to the UB-04 (form CMS-1450) hardcopy form. Those instructions are in the form of a revision to the Medicare Claims Processing Manual and that revision is attached to CR5545. Additional Information If you have any questions, please contact your Medicare FI
or A/B MAC at their toll-free number, which may be found on the
CMS Web site at http://www.cms.hhs.gov/MLNProducts/downloads/CallCenterTollNumDirectory.zip Disclaimer MLN Matters Number: MM5545
|
|||||||||
| Note |
| Note |
| Note |
| Note |




